KBC Group NV Has $5.54 Million Position in Illumina, Inc. (NASDAQ:ILMN)

KBC Group NV boosted its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 2.1% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 42,516 shares of the life sciences company’s stock after acquiring an additional 859 shares during the period. KBC Group NV’s holdings in Illumina were worth $5,544,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the business. Versant Capital Management Inc raised its holdings in shares of Illumina by 292.9% in the 2nd quarter. Versant Capital Management Inc now owns 330 shares of the life sciences company’s stock worth $34,000 after acquiring an additional 246 shares during the last quarter. Industrial Alliance Investment Management Inc. purchased a new stake in shares of Illumina in the second quarter worth approximately $34,000. Massmutual Trust Co. FSB ADV lifted its holdings in shares of Illumina by 65.1% in the third quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock valued at $56,000 after purchasing an additional 168 shares in the last quarter. Itau Unibanco Holding S.A. bought a new position in shares of Illumina in the second quarter valued at approximately $61,000. Finally, Mizuho Securities Co. Ltd. purchased a new position in shares of Illumina during the second quarter valued at approximately $63,000. 89.42% of the stock is owned by institutional investors.

Illumina Price Performance

Shares of NASDAQ ILMN opened at $135.05 on Monday. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43. Illumina, Inc. has a fifty-two week low of $92.69 and a fifty-two week high of $156.66. The stock has a market cap of $21.42 billion, a PE ratio of -13.56 and a beta of 1.13. The stock has a fifty day moving average of $139.66 and a 200-day moving average of $124.31.

Illumina (NASDAQ:ILMN) last posted its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.26. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The business had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.08 billion. During the same quarter in the previous year, the firm earned $0.33 EPS. The company’s quarterly revenue was down 3.5% compared to the same quarter last year. Equities research analysts anticipate that Illumina, Inc. will post 4.11 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ILMN has been the topic of several recent analyst reports. Scotiabank dropped their price objective on Illumina from $176.00 to $164.00 and set a “sector outperform” rating on the stock in a research note on Thursday, August 15th. Citigroup raised their price target on shares of Illumina from $155.00 to $190.00 and gave the company a “buy” rating in a research report on Tuesday, November 5th. UBS Group upped their price objective on shares of Illumina from $133.00 to $145.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Hsbc Global Res upgraded Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 target price on the stock in a research note on Thursday, October 17th. Finally, Piper Sandler decreased their price target on Illumina from $195.00 to $185.00 and set an “overweight” rating for the company in a research report on Monday, November 11th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, fourteen have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Illumina presently has a consensus rating of “Moderate Buy” and a consensus target price of $164.00.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.